These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1484418)

  • 1. [Relation between serum PAP (prostate acid phosphatase) and bone scintigraphy in prostatic cancer].
    Aizawa T; Itoh T; Tsujino S; Namiki K; Miki M
    Kaku Igaku; 1992 Nov; 29(11):1277-83. PubMed ID: 1484418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
    Hetherington JW; Siddall JK; Cooper EH
    Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
    Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
    Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bone scintigraphy, plasma ALP, TAP and PAP in patients with prostatic cancer].
    Imamura A; Hoshi H; Jinnouchi S; Samejima M; Watanabe K
    Kaku Igaku; 1988 Feb; 25(2):177-81. PubMed ID: 3386031
    [No Abstract]   [Full Text] [Related]  

  • 5. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
    Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
    Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
    Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
    J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The usefulness of early whole body bone scintigraphy in the detection of bone metastasis from prostatic cancer].
    Otsuka N; Fukunaga M; Furukawa Y; Tanaka H
    Kaku Igaku; 1994 Jun; 31(6):541-50. PubMed ID: 7520953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase (PAP) in blood by PAP RIA kit "EIKEN" (author's transl)].
    Kida T; Higuchi Y
    Kaku Igaku; 1981 Aug; 18(7):907-15. PubMed ID: 7321322
    [No Abstract]   [Full Text] [Related]  

  • 9. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
    Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
    Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostatic cancer.
    Goodman CM; Cumming JA; Ritchie AW; Chisholm GD
    Br J Urol; 1991 Jun; 67(6):622-5. PubMed ID: 2070208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].
    Morote J; de Torres JA
    Actas Urol Esp; 1990; 14(4):268-70. PubMed ID: 1702258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Flare response on bone scintigraphy in metastatic prostate cancer].
    Aizawa T; Tochimoto M; Ito T; Tsujino S; Akiyama A; Namiki K; Miki M; Ueda M
    Nihon Hinyokika Gakkai Zasshi; 1994 May; 85(5):815-8. PubMed ID: 8022146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
    Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
    N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
    Kida T; Higuchi Y
    Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate.
    Merrick MV; Ding CL; Chisholm GD; Elton RA
    Br J Urol; 1985 Dec; 57(6):715-20. PubMed ID: 4084732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
    Petrone U; Gaspari G; Marascia G; Magnocavallo N; Petrone D; Tucci C
    Minerva Urol Nefrol; 1990; 42(2):73-5. PubMed ID: 1697431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scintigraphic changes in bone metastasis from prostate cancer after hormonal therapy--comparison with tumor markers and bone X-ray.
    Koizumi K; Uchiyama G; Komatsu H
    Ann Nucl Med; 1994 Nov; 8(4):225-30. PubMed ID: 7535550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A reappraisal of serial isotope bone scans in prostate cancer.
    O'Donoghue JM; Rogers E; Grimes H; McCarthy P; Corcoran M; Bredin H; Given HF
    Br J Radiol; 1993 Aug; 66(788):672-6. PubMed ID: 7536607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
    Bantis A; Grammaticos P
    Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.